Abstract
Background: Chronic infection in cystic fibrosis (CF) and airway inflammation leads to progressive lung injury Neutrophils are considered to be responsible for the onset and promotion of the inflammatory response within the CF lung. The relationship between infection and inflammation is complex but circulating inflammatory markers may not truly reflect the local inflammatory response in the lung. The aims of this study were to investigate the change of inflammatory biomarkers and cells within sputum and blood before and after intravenous antibiotics for a pulmonary exacerbation of CF Methods: Assays included neutrophil elastase (NE) and complex, interleukin-8 (IL-8) and soluble intercellular adhesion molecule-1 (sICAM-1), fas ligand (FAS-L), and TNFr-1. Analysis of sputum cell differential and absolute cell counts and immunocytochemistry (CD11b and CD95) on sputum and isolated blood neutrophils were carried out. Results: There were no significant differences in absolute or differential sputum cell counts or sputum sol measurements following antibiotics. There was a significant increase in the percentage of blood neutrophils with minimal CD11b staining, 28 (4.1) mean percentage (SEM) versus41 (2.9) and a decrease in the percentage showing maximal staining 30 (0.5) versus 15 (2.5). There was a significant increase in the percentage of blood neutrophils without CD95 staining, 43 (5.4) mean percentage versus 52 (5.1). Conclusion: These data suggest a modifiable systemic response to IV antibiotics but a local sustained inflammatory response in the lung.
Original language | English |
---|---|
Pages (from-to) | 729-735 |
Number of pages | 7 |
Journal | Pediatric Pulmonology |
Volume | 42 |
Issue number | 8 |
Early online date | 22 Jun 2007 |
DOIs | |
Publication status | Published - Aug 2007 |
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Pulmonary and Respiratory Medicine
Fingerprint
Dive into the research topics of 'The effect of treatment of cystic fibrosis pulmonary exacerbations on airways and systemic inflammation'. Together they form a unique fingerprint.Impacts
-
Improving outcomes for people with cystic fibrosis through evidence based clinical trials
(Participant), Martin, L. (Participant), Downey, D. (Participant), (Participant) & (Participant)
Impact: Health Impact, Quality of Life Impact